Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MESRIX Long-term Follow-up Study
NCT03876197Phase 2Unknown
- Sponsor
- Rigshospitalet
- Start
- Aug 2020
- Primary completion
- Dec 2022
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of autologous adipose-derived mesenchymal stromal cells in hyposalivation, xerostomia, sponsored by Rigshospitalet. Status: unknown.
02
Drugs
autologous adipose-derived mesenchymal stromal cells
03
Conditions
hyposalivationxerostomia
Beyond the preview
Go deeper on NCT03876197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03876197.